Calithera Drops Development Of Lead Candidate Telaglenastat

Interim Phase II Lung Cancer Data Underwhelming

 
• By Ayisha Sharma
  
Telaglenastat Was First Glutaminase Inhibitor In Clinic • Source: Alamy

More from Clinical Trials

More from R&D